RE: DIM16 Jan 2023 07:06
Hvivo/Venn has a nice system where they follow certain markers associated with respiratory infections in the people who paricipate in the human challenge studies carried out by hvivo. This has more to do with predicting disease severity and response to certain drugs and it is very useful data. That being said, it doesn't mean that the database is huge, not in the way that training a deep learning model would require. More importantly, polb extracted potential targets from that data and they are at that stage now. Apart from the likelyhood they probably cannot extract something entirely new from that, it would take years to validate and start clinical trials.
About the obesity treatment, everyone has access to the same drug and trying to make it more bioavailable by the oral route. What polb did is make a deal with another Irish co that makes product for gummies and some food supplements. Even if you want to believe that polb will do a better job here than the largest pharma in the world, thus is still years away from an actual product ready to be tested in humans.
The more I see these exaggerated reports by itrelevant sources (a local paper in Dublin, lmao) the more conviced I become polb is a dud and happy that CF is mo longer directy involved in HVO.